Active, Not Recruiting
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread - CA209-9GW
Updated: 22 July, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com - Patients with metastatic or advanced solid tumors - Women with histologically or cytologically confirmed triple negative breast carcinoma - Participants with histologically or cytologically confirmed pancreatic adenocarcinoma - Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) Exclusion Criteria: - Active brain metastases or leptomeningeal metastases. - Any serious or uncontrolled medical disorder - Prior malignancy active within the previous 3 years Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information